Press Release FeedGet the RSS feed
Menu

Business Wire

XiFin Research Quantifies Millions in Recoverable Revenue Across Ancillary Healthcare Revenue Cycles

Business Wire

New research with Sage Growth Partners identifies three measurable dimensions of unrealized RCM opportunity; radiology practices could recover more than $2.6 million annually through targeted improvements

Findings show that reducing preventable RCM complexity can free significant staff time and resources to be reinvested in patient care

SAN DIEGO, August 27, 2026--XiFin, Inc., a leader in AI-driven revenue cycle management (RCM), today released new research conducted with Sage Growth Partners showing that growing reimbursement complexity, administrative burden, regulatory requirements, and patient financial responsibility are creating significant unrealized revenue cycle opportunity across complex healthcare service lines. Radiology practices, clinical laboratories, pathology groups, specialty pharmacies, and durable medical equipment (DME) providers may be losing recoverable revenue while dedicating substantial resources to preventable rework, manual processes, and patient financial interactions.

The No Surprises Act illustrates how these pressures are increasingly interconnected. Requirements to provide good-faith estimates to uninsured and self-pay patients extend beyond regulatory compliance. Generating and delivering those estimates adds operational complexity and can directly affect an organization's ability to collect earned revenue. Accurate, timely, good-faith estimates help laboratories meet No Surprises Act requirements while improving price transparency, reducing patient billing friction, and supporting a more predictable financial experience.

Detailed in the new research brief, Revealing the Unrealized RCM Upside Your Metrics Miss, the findings identify three interconnected dimensions of revenue cycle opportunity: Revenue Recovery, Operational Efficiency, and Patient Engagement and Access. The brief also introduces a segment-specific framework and reference benchmarks to help providers develop a directional estimate of the potential value of targeted improvements.

The findings are significant. Applied to a mid-sized pathology practice submitting 210,000 claims per year at an average value of $108 per claim, the research identifies approximately $870,000 in combined annual opportunity, including:

  • $430,000 in additional revenue from reducing front-end and back-end denials and underpayments

  • $110,000 in annual cost savings due to opportunities for new operational efficiencies

  • $330,000 in additional revenue collected from patients with amounts due out of pocket, reducing the cost to collect on patient balances, and additional capacity to serve patients annually

  1. HealthcareBeOne Medicines Ltd.BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA
  2. HealthcareCatalYmCatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary and secondary endpoints: pathologic Complete Response (pCR; 33% vs. 8%), radiographic Objective Response Rate (ORR; 60% vs. 15%) and Major Pathologic Response (MPR; 60% vs. 23%) Enhanced responses wer
  3. Real estateSlate Grocery REITSlate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular DetailsTORONTO, October 24, 2026--Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the "REIT"), an owner and operator of U.S. grocery-anchored real estate, announced today that it has obtained an interim order (the "Interim Order") of the Ontario Superior Court of Justice (Commercial List) (the "Court") in conn
  4. Investing & marketsGenesis Healthcare, Inc.Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State StreetKENNETT SQUARE, Pa., October 24, 2026--Genesis Healthcare, Inc. ("Genesis") today announced that its chapter 11 plan became effective, following the closing of the sale of substantially all of its operating assets to 101 W. State Street, LLC ("West State Street") on October 14, 2026. On behalf of the B
  5. BankingUS Metro BancorpUS Metro Bancorp Announces Third Quarter 2026 ResultsGARDEN GROVE, Calif., October 23, 2026--US Metro Bancorp (OTCQX: USMT): US Metro Bancorp ("Bancorp") is a bank holding company, with a single subsidiary, US Metro Bank ("Bank"). On a consolidated basis, Bancorp earned $3.1 million in the third quarter of 2026, compared to $3.5 million in the second qu
  6. Travere Therapeutics, Inc.Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyFILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartan Findings provide further evidence of the biological effects of dual endothelin and angiotensin receptor antagonism and support FILSPARI as foundational treatment in IgAN SAN DIEGO, October 23, 2